A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack

Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic...
This continuing education activity is provided by Vindico Medical Education.

Eyeing the Options for Treating Meibomian Gland Dysfunction and Dry Eye Disease

Dry eye disease (DED) is highly prevalent but frequently underdiagnosed and subsequently undertreated. Studies have demonstrated that meibomian gland dysfunction (MGD) is a leading cause of the development and progression of evaporative DED, caused by a deficient tear film lipid layer that leads to increased tear evaporation. New and emerging treatments with novel mechanisms of action are being investigated that manage the signs and symptoms of DED associated with MGD and offer the potential f...
This continuing education activity is provided by Vindico Medical Education.

Case Challenges in nAMD and DME Management: Achieving Durable Response

The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni...
This continuing education activity is provided by Vindico Medical Education.

Meeting Milestones in nAMD and DME Management: What's New?

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav...
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: An 84-Year-Old Man With Neovascular Age-Related Macular Degeneration Receiving Bilateral Every 8-Week Anti-Vascular Endothelial Growth Factor Injections

In this clinical case review, Dr. Emmanuel Chang explores options to extend treatment intervals in a patient with stable nAMD who is receiving anti-VEGF therapy every 8 weeks.
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: A 65-Year-Old Woman With Chronic Diabetic Macular Edema in Both Eyes

In this clinical case review, Dr. Sara Haug explores considerations for the management of a patient with DME who is receiving monthly anti-VEGF therapy without attaining disease control.
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: A 76-Year-Old Male With Active Neovascular Age-Related Macular Degeneration

In this clinical case review, Dr. Arshad Khanani explores options for switching treatment in a patient with nAMD who has become nonresponsive to anti-vascular endothelial growth factor (VEGF) therapy.
This continuing education activity is provided by Vindico Medical Education.

Secrets of Egypt & the Nile: Joint Medical/Dental Symposium Confronting Healthcare Needs

Uncover Egypt’s ancient secrets with PES for 11 nights on this bucket list adventure! Visit iconic landmarks, temples, and monuments and cruise the Nile in a manner once reserved for pharaohs aboard the luxurious, 72-guest AmaDahlia. Joint Medical/Dental Symposium Confronting Healthcare Needs CME/CE Lecture Seminars for Medical, Dental, Nursing, and Allied Healthcare Professionals This Seminar is planned for 14 Continuing Education Credit Hours. CME/CE Professional Seminar Fee:...
Professional Education Society

Recognition and Referral: Best Practices for Managing Patients with GA

Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ...
Evolve Medical Education LLC

Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment

This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced. Case discussions and audience question-and-answer session were also recorded.
Evolve Medical Education LLC

Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents

Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma.
Evolve Medical Education LLC

Neurotrophic Keratitis: Old Problem, New Solutions

Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments.
Evolve Medical Education LLC

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map